Mediator of ERBB2-driven Cell Motility (MEMO) Promotes Extranuclear Estrogen Receptor Signaling Involving the Growth Factor Receptors IGF1R and ERBB2

Kai Jiang,† Zhihong Yang,† Long Cheng,† Shibin Wang,§,†, Kang Ning,§,†, Lei Zhou,§,†, Jing Lin,§,†, Hui Zhong,†, Lisheng Wang,‡,§,†, Yang Li,‡,§, Junjian Huang,‡, Hao Zhang,‡,§, and Qinong Ye‡,§

From the †Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing 100850, the ‡Department of General Surgery, First Affiliated Hospital, Chinese PLA General Hospital, Beijing 100037, the §§A Liaoning Center for Disease Control and Prevention, Liaoning 110005, the ¶Department of Tumor, Shijitan Hospital, Beijing 100038, the **Department of Clinical Laboratory, First Affiliated Hospital, Chinese PLA General Hospital, Beijing 100037, and the ***Department of Experimental Hematology, Beijing Institute of Radiation Medicine, Beijing 1000850, China

Received for publication, March 8, 2013, and in revised form, July 16, 2013 Published, JBC Papers in Press, July 16, 2013, DOI 10.1074/jbc.M113.467837

Background: Extranuclear ER plays an important role in cancer cell growth regulation through activation of kinase cascades. MEMO modulates extranuclear functions of ER as well as breast cancer cell growth. MEMO is a new component of extranuclear ER signalosome and is essential for the regulation of ER-positive breast cancer cell growth. MEMO might be an interesting target for ER-positive breast cancer therapy.

In addition to nuclear estrogen receptor (ER) acting as a transcription factor, extranuclear ER also plays an important role in cancer cell growth regulation through activation of kinase cascades. However, the molecular mechanisms by which extranuclear ER exerts its function are still poorly understood. Here, we report that mediator of ERBB2-driven cell motility (MEMO) regulates extranuclear functions of ER. MEMO physically and functionally interacted with ER. Through its interaction with the growth factor receptors IGF1R and ERBB2, MEMO mediated extranuclear functions of ER, including activation of mitogen-activated protein kinase (MAPK) and protein kinase B/AKT, two important growth regulatory protein kinases, and integration of function with nuclear ER. Activation of MAPK and AKT was responsible for MEMO modulation of ER phosphorylation and estrogen-responsive gene expression. Moreover, MEMO increased anchorage-dependent and independent growth of ER-positive breast cancer cells in vitro and was required for estrogen-induced breast tumor growth in nude mice. Together, our studies identified MEMO as a new component of extranuclear ER signalosome and suggest an essential role for MEMO in the regulation of ER-positive breast cancer cell growth.

Estrogen plays a critical role in the development and progression of estrogen-related cancers such as breast cancer (1, 2). Estrogen exerts its biological responses through estrogen receptor (ER) α and β to regulate networks of gene transcription. ER belongs to a superfamily of ligand-activated transcription factors that share structural similarity characterized by several functional domains. The N-terminal estrogen-independent and C-terminal estrogen-dependent activation function domains (AF1 and AF2, respectively) contribute to the transcriptional activity of the two receptors. The DNA binding domain of ER is centrally located. The ligand binding domain, overlapping AF2, shows 58% homology between ERα and ERβ. The DNA binding domain is identical between the two receptors except for three amino acids. However, the AF1 domain of ERβ has only 28% homology with that of ERα. Traditionally, ER is thought to be ligand-activated nuclear transcription factors that bind to estrogen-response elements (ERE) of target genes. Upon binding to DNA, ER regulates target gene transcription through recruitment of coactivators and corepressors. Although the majority of ER is in the nucleus mediating both ligand-dependent and ligand-independent gene transcription, evidence from an increasing number of studies clearly shows that a small population of ER is localized at or near the plasma membrane in the presence or absence of estrogen and mediates rapid extranuclear functions of ER (3–7). Extranuclear ER signaling pathway involves insulin-like growth factor 1 receptor (IGF1R) and epidermal growth factor receptor (EGFR), resulting in the activation of many signaling molecules, such as mitogen-activated protein kinase (MAPK), protein kinase B/AKT, and intracellular second messengers (8). MAPK and AKT can phosphorylate ERα, thereby increasing

© 2013 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.

THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 288, NO. 34, pp. 24590 –24599, August 23, 2013
24590 JOURNAL OF BIOLOGICAL CHEMISTRY }

VOLUME 288 • NUMBER 34 • AUGUST 23, 2013

24590 JOURNAL OF BIOLOGICAL CHEMISTRY }

VOLUME 288 • NUMBER 34 • AUGUST 23, 2013

24590 JOURNAL OF BIOLOGICAL CHEMISTRY }

VOLUME 288 • NUMBER 34 • AUGUST 23, 2013

24590 JOURNAL OF BIOLOGICAL CHEMISTRY }

VOLUME 288 • NUMBER 34 • AUGUST 23, 2013

24590 JOURNAL OF BIOLOGICAL CHEMISTRY }
ERα transcriptional activity (9–14). In cultured cancer cells, membrane-initiated ERα signaling mediates the proliferative effects of estrogen. However, the molecular mechanisms by which extranuclear ER exerts its function are still poorly understood.

The mediator of ERBB2-driven cell motility (MEMO) is a 297-amino acid protein and is not homologous to any known signaling protein (15, 16). The biological function of MEMO is largely unknown. MEMO interacts with ERBB2 and is required for breast cancer cell migration (15, 17). ERBB2 is a member of the epidermal growth factor (EGF, also known as ErbB) family of receptor tyrosine kinases, which also includes EGFR, ErbB3, and ErbB4 (18). MEMO controls ERBB2-regulated microtubule dynamics (19). In this study, we have identified MEMO as a novel ER-interacting protein. Through its interaction with IGFR1 and ERBB2, MEMO regulates extranuclear functions of ERα, such as activation of MAPK and AKT pathways and integration of function with nuclear ERα that functions as a transcription factor. Importantly, MEMO is required for estrogen-mediated breast tumor growth.

**EXPERIMENTAL PROCEDURES**

**Plasmids and siRNAs**—The estrogen-responsive reporterERE-Lucand eukaryotic expression vectors for FLAG-tagged ERα and ERβ have been described previously (20). The extranuclear ERα mutant ERα (H2+NES) was constructed as reported previously (21). Other mammalian expression vectors encoding FLAG or Myc fusion proteins tagged at the N terminus were constructed by inserting PCR-amplified fragments into pcDNA3 (Invitrogen) or pIRESpuro2 (Clontech). Enhanced green fluorescent protein-tagged MEMO construct was generated by inserting MEMO cDNA into pEGFP-C1 (Clontech). Plasmids encoding GST fusion proteins were made by cloning PCR-amplified sequences into pGEX-KG (Amersham Biosciences). Plasmids encoding GST fusion proteins were made by cloning PCR-amplified sequences into pGEX-KG (Amersham Biosciences). Plasmids encoding GST fusion proteins were made by cloning PCR-amplified sequences into pGEX-KG (Amersham Biosciences). Plasmids encoding GST fusion proteins were made by cloning PCR-amplified sequences into pGEX-KG (Amersham Biosciences). Plasmids encoding GST fusion proteins were made by cloning PCR-amplified sequences into pGEX-KG (Amersham Biosciences). Plasmids encoding GST fusion proteins were made by cloning PCR-amplified sequences into pGEX-KG (Amersham Biosciences).

**Chromatin Immunoprecipitation Assay (ChIP)** —ChIP assays were performed as described previously with the primers listed in supplemental Table 1A (25).

**Real Time RT-PCR** —Total RNA was isolated using TRIzol reagent (Invitrogen) and reverse-transcribed using SuperScript II reverse transcriptase (Invitrogen). Real-time PCR was performed as described previously with the primers listed in supplemental Table S1B.

**Anchorage-dependent growth** — Anchorage-dependent cell growth was determined by a crystal violet assay as described previously (22). For anchorage-independent growth (22), 1 × 10⁴ cells were plated on 6-cm plates containing a bottom layer of 0.6% low melting temperature agar in DMEM and a top layer of 0.3% agar in DMEM. Colonies were scored after 3 weeks of growth.

**Animal Experiments** —Animal studies were approved by the Institutional Animal Care Committee of Beijing Institute of Biotechnology. Two days after implantation of estrogen pellets (E₂, 0.36 mg/pellet, 60-day release) (Innovative Research of America), 1 × 10⁵ tumor cells were injected into the abdominal mammary fat pad of 6-week-old female nude mice. Tumor growth was monitored by caliper measurements. Excised tumors were weighed, and portions were frozen in liquid nitrogen or fixed in 4% paraformaldehyde for further study.

**Statistical Analysis** —Differences between variables were assessed by two-tailed Student’s t test or one-way analysis of variance. Statistical calculations were performed using SPSS13.0. A p value <0.05 was considered statistically significant.
MEMO Modulation of Extranuclear ER

RESULTS

MEMO Interacts with ER in Vitro and in Vivo—Yeast two-hybrid screening of a human mammary cDNA library, with the AF1 domain of ERα as bait, identified human MEMO as an ERα-interacting protein (supplemental Fig. 1). Transformation of yeast cells with MEMO together with the controls did not activate the His, Ade, and lacZ reporter genes, indicating the specific interaction of MEMO with ERα in yeast cells. GST pulldown and coimmunoprecipitation assays further demonstrated that MEMO interacted with ERα and ERβ in vitro and in 293T cells in the absence or presence of 17β-estradiol (E2) (Fig. 1, A–C). Importantly, endogenous MEMO associated with ERα in MCF7 breast cancer cells (Fig. 1D). Moreover, subcellular fractionation experiments showed that in MCF7, ZR75-1, and T47D breast cancer cells MEMO resided in the cytoplasm but not in the nucleus (supplemental Fig. 2). Endogenous cytoplasmic MEMO also interacted with endogenous cytoplasmic ERα in MCF7 cells (Fig. 1E).

MEMO Activates MAPK and AKT and Subsequent ERα Phosphorylation—Because MEMO associates with extranuclear ERα, we tested whether MEMO regulates rapid extranuclear functions of ER, such as activation of MAPK/extracellular signal-regulated kinases 1 and 2 (ERK1/2) and AKT (6). As expected, E2 rapidly increased phosphorylation of ERK1/2 and AKT in MCF7 cells, which was seen from 5 to 30 min after E2 treatment (Fig. 2A and data not shown). Importantly, overexpression of MEMO enhanced phosphorylation of ERK1/2 and AKT in both the absence and the presence of E2. In contrast, stable knockdown of MEMO with MEMO siRNAs reduced ERK1/2 and AKT phosphorylation (Fig. 2B).

Although ERβ phosphorylation is largely unknown, ERα has been shown to be phosphorylated at serines (Ser) 104, 106, and 118 by MAPK (9–12). ERα Ser-167 can be phosphorylated by AKT (13, 14). Because MEMO can activate MAPK and AKT, we determined whether MEMO increases phosphorylation of ERα. Indeed, overexpression of MEMO in MCF7 cells increased phosphorylation of ERα at serines 104, 106, 118, and 167 (Fig. 2A), whereas stable knockdown of MEMO decreased ERα phosphorylation at these sites (Fig. 2B). Similar results were obtained in ZR75-1 cells (supplemental Fig. 3, A and B). Moreover, ERα is required for MEMO activation of MAPK and AKT because knockdown of endogenous ERα in MCF7 cells abolished the ability of MEMO to regulate MAPK and AKT (Fig. 2C), suggesting the importance of the interaction between MEMO and ERα. Similar results were observed in ERα-negative HEK293T cells. More importantly, MEMO could activate MAPK and AKT through extranuclear ERα because the previously reported extranuclear ERα mutant Erα(H2+NES) was sufficient for MEMO modulation of MAPK and AKT (21) (supplemental Fig. 3C).

To determine whether estrogen antagonists affect MEMO-induced MAPK and AKT activation as well as ERα phosphorylation, the mixed agonist/antagonist 4-OHT and the pure antagonist ICI182,780 were used. Tamoxifen and ICI182,780 treatment in control siRNA-transfected MCF7 cells had similar effects to those in MEMO siRNA-transfected MCF7 cells, i.e. tamoxifen and ICI182,780 antagonized estrogen-mediated effects in both control siRNA- and MEMO siRNA-transfected MCF7 cells (Fig. 2D).

MEMO Enhances ERα Transcriptional Activity through Increased ERα Phosphorylation and ERα Recruitment to Estrogen-responsive Promoters—It has been shown that extranuclear ER can indirectly regulate ER transcriptional activity through ER phosphorylation (26). As MEMO can regulate ER phosphorylation, we determined whether MEMO affects ER transcriptional activity. MEMO overexpression in ERα- and ERβ-negative SKBR3 breast cancer cells increased transcription of a luciferase reporter construct containing the estrogen-responsive element (ERE) in an ERα- or ERβ-dependent manner in the presence or absence of E2 (Fig. 3A). Moreover, MEMO increased ER transcriptional activity in ERα- and ERβ-positive MCF7 cells regardless of E2, the ERα-specific agonist propylpyrazole triol, and the ERβ-specific agonist diarylpropionitrile.
MEMO regulates ER transcriptional activity in a ligand-independent manner. Similar results were observed in ERα-positive ZR75-1 and T47D cells (supplemental Fig. 4, B and C). Consistent with the results of MEMO overexpression, knockdown of endogenous MEMO in MCF7 cells decreased ERE-Luc reporter activity independently of ligands, including EGF and IGF, which have been reported to stimulate ER transcriptional activity through ER phosphorylation (Fig. 3C) (10). Importantly, MEMO increased wild-type ERα-mediated ERE-LUC reporter transcription much greater than the ERE-LUC reporter transcription mediated by mutant ERα in which serines 104, 106, 118, and 167 were mutated to alanine (Fig. 3D). These data suggest that phosphorylation of ERα at these sites is critical for the enhancement of ERα transcriptional activity by MEMO.

To investigate whether MEMO affects promoter occupancy of ERα, we performed ChIP experiments for the estrogen-responsive pS2, c-Fos, and CCND1 promoters. As expected, ERα was recruited to the pS2, c-Fos, and CCND1 promoters but not to a region ~2-kb upstream of the pS2, c-Fos, or CCND1 promoters (Fig. 3E). Importantly, MEMO knockdown decreased ERα recruitment to the c-Fos and CCND1 promoters, but not the pS2 promoter, indicating that MEMO selectively regulates ERα recruitment to estrogen-responsive promoters.

MEMO Increases ERα Target Gene Expression through Activation of MAPK and AKT and Subsequent ERα Phosphorylation—To validate the reporter assays in which MEMO increases ERα transcriptional activity, we performed real-time RT-PCR analysis using MCF7 cells stably transfected with MEMO siRNA or control siRNA. The results showed that, in the presence or absence of E2, MEMO knockdown reduced the transcription of eight previously reported E2-regulated genes (Fig. 4A), including c-Fos (cellular FBJ osteosarcoma oncogene), c-Jun (cellular junana), cathepsin D, CCND1/cyclin D1, c-myc (cellular myelocytomatosis virus oncogene), STC2 (stanniocalcin 2), PCP4 (Purkinje cell protein 4), and CA2 (carbonic anhydrase 2), many of which play key roles in cell proliferation regulation (27–30). Consistent with the results of ChIP experiments, MEMO did not alter pS2/TFF1 (trefoil factor 1) mRNA expression (Fig. 4A). In addition, MEMO did not regulate ERα mRNA expression. Importantly, stable MEMO expression in MCF7 cells increased the protein levels of c-Fos, c-Jun, cathepsin D, cyclin D1, and c-Myc, but not pS2, in an E2-independent manner (Fig. 4B). In contrast, siRNA knockdown of endogenous MEMO in MCF7 cells reduced the protein expression of c-Fos, c-Jun, cathepsin D, cyclin D1, and c-Myc, but not pS2 (Fig. 4C), suggesting that MEMO selectively regulates estrogen-responsive gene expression. Similar results were obtained in (Fig. 3B and supplemental Fig. 4C), suggesting that MEMO regulates ER transcriptional activity in a ligand-independent manner. Similar results were observed in ERα-positive ZR75-1 and T47D cells (supplemental Fig. 4, B and C). Consistent with the results of MEMO overexpression, knockdown of endogenous MEMO in MCF7 cells decreased ERE-Luc reporter activity independently of ligands, including EGF and IGF, which have been reported to stimulate ER transcriptional activity through ER phosphorylation (Fig. 3C) (10). Importantly, MEMO increased wild-type ERα-mediated ERE-LUC reporter transcription much greater than the ERE-LUC reporter transcription mediated by mutant ERα in which serines 104, 106, 118, and 167 were mutated to alanine (Fig. 3D). These data suggest that phosphorylation of ERα at these sites is critical for the enhancement of ERα transcriptional activity by MEMO.

To investigate whether MEMO affects promoter occupancy of ERα, we performed ChIP experiments for the estrogen-responsive pS2, c-Fos, and CCND1 promoters. As expected, ERα was recruited to the pS2, c-Fos, and CCND1 promoters but not to a region ~2-kb upstream of the pS2, c-Fos, or CCND1 promoters (Fig. 3E). Importantly, MEMO knockdown decreased ERα recruitment to the c-Fos and CCND1 promoters, but not the pS2 promoter, indicating that MEMO selectively regulates ERα recruitment to estrogen-responsive promoters.

MEMO Increases ERα Target Gene Expression through Activation of MAPK and AKT and Subsequent ERα Phosphorylation—To validate the reporter assays in which MEMO increases ERα transcriptional activity, we performed real-time RT-PCR analysis using MCF7 cells stably transfected with MEMO siRNA or control siRNA. The results showed that, in the presence or absence of E2, MEMO knockdown reduced the transcription of eight previously reported E2-regulated genes (Fig. 4A), including c-Fos (cellular FBJ osteosarcoma oncogene), c-Jun (cellular junana), cathepsin D, CCND1/cyclin D1, c-myc (cellular myelocytomatosis virus oncogene), STC2 (stanniocalcin 2), PCP4 (Purkinje cell protein 4), and CA2 (carbonic anhydrase 2), many of which play key roles in cell proliferation regulation (27–30). Consistent with the results of ChIP experiments, MEMO did not alter pS2/TFF1 (trefoil factor 1) mRNA expression (Fig. 4A). In addition, MEMO did not regulate ERα mRNA expression. Importantly, stable MEMO expression in MCF7 cells increased the protein levels of c-Fos, c-Jun, cathepsin D, cyclin D1, and c-Myc, but not pS2, in an E2-independent manner (Fig. 4B). In contrast, siRNA knockdown of endogenous MEMO in MCF7 cells reduced the protein expression of c-Fos, c-Jun, cathepsin D, cyclin D1, and c-Myc, but not pS2 (Fig. 4C), suggesting that MEMO selectively regulates estrogen-responsive gene expression. Similar results were obtained in...
MEMO Modulation of Extranuclear ER

Such inhibition impaired the effect of MEMO on the expression of the estrogen-responsive proteins cyclin D1 and c-Fos. These data suggest that MEMO increases ERα phosphorylation and estrogen-responsive gene expression at least in part through activated MAPK and AKT.

**MEMO and ERα Interaction Is Required for Activation of MAPK and AKT as Well as Estrogen-responsive Gene Expression**—To further determine whether the interaction of MEMO and ERα is necessary for activation of MAPK and AKT as well as estrogen-responsive gene expression, we first used deletion analysis to map the interaction domains of ERα in coimmunoprecipitation assays. The AF1 and AF2 domains of ERα interacted with MEMO, whereas the ERα DNA binding domain did not (Fig. 5A).

Next, we determined which MEMO protein region mediates interaction with ERα by GST pulldown assay. GST-MEMO(75–146) and GST-MEMO(140–211) bound ERα, whereas GST-MEMO(1–81), GST-MEMO(205–297), or GST alone did not (Fig. 5B). The MEMO(75–146) and the MEMO(140–211) interacted with ERα more weakly than full-length MEMO, suggesting that both regions of MEMO are required for maximal interaction with ERα. The AF1 and AF2 domains of ERα also interacted with MEMO, whereas the ERα DNA binding domain did not (Fig. 5A).
interaction of MEMO with ERα (Fig. 5D). Importantly, the MEMO(Δ82–204) deletion mutant, which lacks two ERα-binding sites, or the MEMO(Δ161–204) deletion mutant, which greatly reduces the interaction of MEMO with ERα, completely or almost abolished the ability of MEMO to activate MAPK and AKT, ERα phosphorylation, and estrogen-responsive gene expression (Fig. 5E). Combined with the previous results (Fig. 2C), these data suggest that interaction of MEMO with ERα is required for MEMO modulation of ERα function.

**MEMO Activation of MAPK and AKT Requires IGF1R and ErbBs**—Phosphorylation of MAPK and AKT plays a critical role in transducing signals from membrane ER to nuclear ER (6). ER has no intrinsic kinase domain and thus is not capable of phosphorylating other proteins. Like ER, MEMO also did not have intrinsic kinase activity by an in vitro kinase assay (data not shown). It has been reported that ER initiates E2 rapid non-genomic signals by forming a protein complex with many signaling molecules, including IGF1R and EGFR/ErbB1, which have kinase activities (31). The formation of the protein complex leads to the activation of MAPK and AKT pathways. MEMO has been shown to interact with ERBB2, another EGFR family member (15). Thus, we hypothesized that MEMO may activate MAPK and AKT through its interaction with IGF1R and the members of the EGFR family. Indeed, GST pulldown experiments showed that MEMO interacted not only with IGF1R but also with the EGFR family members ErbB1–4 (Fig. 6A). As a control, MEMO did not interact with the nonreceptor tyrosine kinase c-Abl (cellular Abelson leukemia oncogene). These results suggested that MEMO, ERα, and IGF1R or ErbBs might coexist in the same functional complex. To verify this, we performed reciprocal coimmunoprecipitation assays with each of the antibodies against these proteins. MEMO, ERα, IGF1R, and ERBB2 could form a protein complex in MCF7 cells (Fig. 6B).

Next, we investigated whether MEMO activates MAPK and AKT through IGF1R and ERBB2. Knockdown of endogenous IGF1R or ERBB2 in MCF7 cells greatly attenuated MEMO activation of ERK1/2 and AKT, leading to reduced phosphorylation of ERα at serines 104, 106, 118, and 167 as well as reduced expression of the estrogen-responsive genes c-Fos and cyclin D1 (Fig. 6, C and D). These results suggest that MEMO activates MAPK and AKT and subsequent ER targets through IGF1R and ERBB2.

**MEMO Is Required for Estrogen-mediated Breast Tumor Growth**—Next, we determined the effect of MEMO on breast cancer cell growth. In assays of anchorage-dependent growth,
MCF7 cells stably transfected with MEMO grew faster than those transfected with empty vector both in the presence and in the absence of E2 (Fig. 7A). The above-mentioned deletion mutants, MEMO(Δ82–204) and MEMO(Δ161–204), completely or almost abolished the ability of MEMO to increase the growth of MCF7 cells. In contrast, MEMO knockdown greatly reduced E2-mediated growth stimulation of MCF7 cells (Fig. 7B), and this phenomenon was rescued by MEMO re-expression. Similar results were observed in ZR75-1 cells (supplemental Fig. 5, A and B). As determined by anchorage-dependent

FIGURE 7. MEMO is required for ERα-positive breast tumor growth. A, anchorage-dependent growth assays in MCF7 cells transfected with FLAG-tagged MEMO, MEMO(Δ82–204), or MEMO(Δ161–204) with or without 10 nM E2 treatment. Cell viability was assessed at the indicated times. Data are presented as means ± S.D. of three independent experiments. Bottom, immunoblot analysis with anti-FLAG. B, anchorage-dependent growth assays in MCF7 cells transfected with MEMO siRNA1 or MEMO siRNA1 plus siRNA-resistant MEMO. Cells were treated and analyzed as in A. Bottom, immunoblot analysis with anti-MEMO. C, MCF7 cells stably transfected with control siRNA or MEMO siRNA1 were treated with different doses of 4-OHT or ICI182,780. Cell viability was assessed 5 days after treatment. D, anchorage-independent growth assays in MCF7 cells transfected as in B. Scale bar, 50 μm. E and F, volume of xenograft tumors derived from MCF7 (E) or ZR75-1 (F) cells expressing control siRNA or MEMO siRNA1. Detailed tumor volumes were listed in the table (F). Data are presented as mean ± S.D. (n = 10). Representative tumor tissues were subjected to immunoblot analysis with the indicated antibodies (F, right panel). *, p < 0.01 versus empty vector or control siRNA without E2. #, p < 0.01 versus empty vector or control siRNA with E2. $, p < 0.05 versus empty vector or control siRNA without E2. &, p < 0.05 versus empty vector or control siRNA with E2.
growth assays, knockdown of MEMO reduced the sensitivity of MCF7 cells to the estrogen antagonists 4-OHT and ICI182,780 (Fig. 7C). MEMO knockdown also greatly inhibited anchorage-independent growth of MCF7 and ZR75-1 cells in the presence or absence of E2 (Fig. 7D and supplemental Fig. 5, C and D), and again, the observed effects were rescued by MEMO re-expression in MCF7 cells (Fig. 7D). Furthermore, all mice inoculated with MCF7 or ZR75-1 cells expressing control siRNA developed tumors in the presence of E2, but not in the absence of E2 (Fig. 7, E and F; and data not shown), suggesting that both MCF7 and ZR75-1 cell lines are estrogen-dependent. In contrast, none of the mice inoculated with MCF7 cells expressing MEMO siRNA developed tumors in the presence of E2 (Fig. 7E), and mice inoculated with ZR75-1 cells expressing MEMO siRNA showed late latency and a much smaller tumor size (Fig. 7F). The tumors in mice inoculated with ZR75-1 cells expressing MEMO siRNA had reduced phosphorylation of ERK1/2, AKT, ERα(Ser-104 and Ser-106), ERα(Ser-118), and ERα(Ser-167), as well as expression of c-Fos and cyclin D1 (Fig. 7F).

**DISCUSSION**

In this study, we have identified MEMO as a new component of extranuclear ERα signaling. MEMO integrates extranuclear and nuclear ERα actions. Importantly, MEMO plays an essential role in ERα-positive breast cancer cell growth through regulation of many growth-related genes. Thus, the findings provide novel mechanistic insights into the growth of ERα-positive breast cancer cells, the number of which increases during breast cancer development.

Several membrane and cytoplasmic adaptor proteins, including caveolins (32, 33), striatin (34), p130Cas (35), the adaptor protein She (36), hematopoietic PBX-interacting protein (37, 38), and modulator of nongenomic action of estrogen receptor/proline-, glutamic acid-, and leucine-rich protein (MNAR/PELP1) (39), have been shown to interact with membrane/cytoplasmic ERα. E2 increases the interaction of ERα with these proteins. However, MEMO interacts with ERα and regulates ERα transcriptional activity in an E2-independent manner. It has been reported that stimulation of numerous growth factor receptors leads to a ligand-independent increase in ERα transcription, presumably by ERα phosphorylation (10). Indeed, MEMO forms a complex with the growth factor receptors IGF1R and ERBB2, resulting in the phosphorylation of the ligand-independent AF1 domain of ERα. The fact that E2-independent activation of ERα by MEMO suggests that MEMO may play roles in the development and progression of both E2-independent and -dependent cancers. Because two to three proteins are usually studied for protein-protein interaction, whether there is more than one extranuclear ERα-containing complex remains to be investigated.

Extranuclear ERα initiates rapid action response by binding to estrogen. Although we grew cells with phenol red-free DMEM supplemented with 10% charcoal-stripped FBS, there may be residual estrogens in the culture media, which activate rapid estrogen response, followed by ERα phosphorylation and transcriptional activation. In addition, the charcoal-stripped FBS also contained many growth factors, which activate growth factor signaling and may cross-talk with estrogen signaling (40). The fact that knockdown of MEMO can inhibit basal ERα transcriptional activity and MEMO regulates ERα transcriptional activity in a ligand-independent manner suggests that a small amount of estrogen may be sufficient for MEMO modulation of ERα transcriptional activation.

It has been shown that the ligand-independent activity of ERα is a result of ERα phosphorylation at multiple sites, including serines 104, 106, 118, 167, and 305 (41). Phosphorylation of ERα at these sites increases ERα transcriptional activity. However, the clinical significance of ERα phosphorylation at these sites is complicated. It has been reported that phosphorylation at some sites in ERα is associated with a better clinical outcome, whereas phosphorylation at other sites is associated with a poorer clinical outcome most often in patients treated with tamoxifen (42). For instance, ERα phosphorylation at serine 118 or 167 is associated with a better clinical outcome in patients treated with tamoxifen, whereas elevated phosphorylation at serine 305 predicts tamoxifen resistance. The clinical significance of ERα phosphorylation at serines 104 and 106 is unknown. Our study showed that MEMO increased ERα phosphorylation at serines 104, 106, 118, and 167, and tamoxifen antagonized such effect. Moreover, knockdown of MEMO induced tamoxifen resistance in cultured breast cancer cells. It will be interesting to determine whether MEMO is a predictive marker in breast cancer patients treated with tamoxifen.

Overexpression of ERBB2 is associated with aggressive breast tumors that are more likely to metastasize (18). MEMO was shown to be required for ERBB2-driven breast cancer cell migration (15). Whether MEMO has other biological functions remains unknown. We demonstrate that MEMO plays an essential role in ERα-positive breast cancer cell growth. MEMO not only activates MAPK and AKT, two important growth regulatory protein kinases (43), but also enhances the expression of many growth-related estrogen-responsive proteins, including c-Fos (44), c-Jun (45), cyclin D1 (46), and c-myc (47). c-Fos and c-Jun belong to the activating protein-1 (AP-1) transcription factor that plays a critical role in tumorigenesis and progression. They regulate the expression of AP-1 target genes by forming heterodimer (c-Jun/c-Fos) or homodimer (c-Jun/c-Jun) and by binding to the AP-1 site within gene promoters. Both c-Fos and c-Jun are overexpressed in human breast cancer. c-Fos knockdown with antisense cDNA suppresses breast cancer cell growth. c-Jun overexpression in MCF7 cells produces a tumorigenesis-, invasive-, and hormone-resistant phenotype. Overexpression of cyclin D1 is common in human cancers of epithelial cell origin. Cyclin D1 is required for mammary tumorigenesis induced by ERBB2. Like cyclin D1, c-Myc is also overexpressed in breast tumors. Overexpression of c-Myc contributes to breast cancer development and progression and is associated with poor clinical outcome. The fact that MEMO can regulate many key oncogenes suggests the importance of MEMO in breast cancer development and progression and as a therapeutic target.

MCF7 and ZR75-1 are two well characterized ERα-positive breast cancer cell lines. In our study, ZR75-1 cells are easier to form tumors in the presence of estrogen in nude mice than MCF7 cells. This may be due to differential gene expression profiling between the two cell lines. It has been reported that
MEMO Modulation of Extranuclear ER

ZR75-1 cells selectively use genes for energy, protein synthesis, and sugar metabolism and other pathways differently from MCF7 cells (48). Such characteristics may impart more aggressiveness to ZR75-1 than MCF7. The difference in gene expression between MCF7 and ZR75-1 cells may also affect the ability of MEMO to regulate breast cancer cell growth in nude mice. None of the mice inoculated with MEMO siRNA-expressing MCF7 cells developed tumors in the presence of E2, and mice inoculated with MEMO siRNA-expressing ZR75-1 cells revealed late latency and a much smaller tumor size. Although MEMO siRNA-expressing ZR75-1 tumors grew with similar kinetics to control tumors 2–6 weeks after inoculation, significant different kinetics seems to be observed 7 weeks after inoculation. This trend might be more obvious if tumors had grown for more than 7 weeks.

Overexpression of ERBB2 occurs in ~30% of breast cancer and is associated with poor clinical outcome such as shorter survival and shorter time to relapse (18). ERBB2 is therefore an attractive target for drug development. Accordingly, humanized monoclonal antibodies against ERBB2 (Herceptin®, trastuzumab) have been developed and used in the treatment of patients with breast cancer overexpressing ERBB2. However, not all patients whose tumors overexpress ERBB2 respond to trastuzumab treatment (49). The mechanisms underlying trastuzumab resistance include the inability or reduced capacity of trastuzumab binding to ERBB2 and activation of downstream signaling pathways such as PI3K/AKT signaling. In some breast cancer patients, trastuzumab is unable to interfere with the ERBB2 heterodimers by EGF or ErbB3. Interaction of ERBB2 with other proteins such as mucin-4 sterically hinders ERBB2 binding to trastuzumab (49). Activation of PI3K/AKT signaling has been considered as the major determinant of trastuzumab resistance. Trastuzumab-mediated growth inhibition was lost in breast cancer cells that overexpressed both IGFR1 and ERBB2. This may be due to cross-talk between IGF1R and ERBB2 signaling (50). IGFR1 and ERBB2 interact with each other and synergistically stimulate PI3K/AKT signaling. The findings that MEMO, ERα, IGFR1, and ERBB2 form a complex and MEMO activates the AKT pathway raise the possibility that MEMO may be involved in trastuzumab resistance. Whether MEMO prevents ERBB2 from binding to trastuzumab remains to be elucidated. The essential role of MEMO in ERe-positive breast tumor growth might make it an interesting target for breast cancer therapy.

REFERENCES

1. Deroo, B. J., and Korach, K. S. (2006) Estrogen receptors and human disease. J. Clin. Invest. 116, 561–570
2. Yager, J. D., and Davidson, N. E. (2006) Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354, 270–282
3. Levin, E. R., and Pietras, R. J. (2008) Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res. Treat. 108, 351–361
4. Fu, X. D., and Simoncini, T. (2008) Extranuclear signaling of estrogen receptors. IUBMB Life 60, 502–510
5. Boonyaratankornkit, V. (2011) Scaffolding proteins mediating membrane-initiated extranuclear actions of estrogen receptor. Steroids 76, 877–884
6. Pietras, R. J., and Márquez-Garbán, D. C. (2007) Membrane-associated estrogen receptor signaling pathways in human cancers. Clin. Cancer Res. 13, 4672–4676
7. Song, R. X., and Santen, R. J. (2006) Membrane-initiated estrogen signaling in breast cancer. Biol. Reprod. 75, 9–16
8. Song, R. X., Chen, Y., Zhang, Z., Bao, Y., Yue, W., Wang, J. P., Fan, P., and Santen, R. J. (2010) Estrogen utilization of IGF-1-R and EGR-F to signal to breast cancer cells. J. Steroid Biochem. Mol. Biol. 118, 219–230
9. Thomas, R. S., Sarwar, N., Phoenix, F., Coombes, R. C., and Ali, S. (2008) Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity. J. Mol. Endocrinol. 40, 173–184
10. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., Metzger, D., and Chambon, P. (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491–1494
11. Joel, P. B., Traish, A. M., and Lannigan, D. A. (1995) Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol. Endocrinol. 9, 1041–1052
12. Bunone, G., Briand, P. A., Miksicek, R. J., and Picard, D. (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15, 2174–2183
13. Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., and Luo, J. K. (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407, 538–541
14. Martin, M. B., Franke, T. F., Stoica, G. E., Chambon, P., Katzenellenbogen, B. S., Stoica, B. A., McLemore, M. S., Olivo, S. E., and Stoica, A. (2000) A role for Akt in mediating the estrigenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141, 4503–4511
15. Marone, R., Hess, D., Dankort, D., Muller, W. J., Hynes, N. E., and Badache, A. (2004) Memo mediates ErbB2-driven cell motility. Nat. Cell Biol. 6, 515–522
16. Qiu, C., Lienhard, S., Hynes, N. E., Badache, A., and Leahy, D. J. (2008) Memo is homologous to nonheme iron dioxygenases and binds an ErbB2-derived phosphate peptide in its vesigial active site. J. Biol. Chem. 283, 2734–2740
17. Meira, M., Masson, R., Stagljar, I., Lienhard, S., Maurer, F., Boulay, A., and Hynes, N. E. (2009) Memo is a cofillin-interacting protein that influences PLCγ1 and cofillin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration. J. Cell Sci. 122, 787–797
18. Bazley, L. A., and Gullck, W. J. (2005) The epidermal growth factor receptor family. Endocr. Relat. Cancer 12, S17–27
19. Zaoui, K., Honoré, S., Isnardon, D., Braguer, D., and Badache, A. (2008) Memo-RhoA-mDia1 signaling controls microtubes, the actin network, and adhesion site formation in migrating cells. J. Cell Biol. 183, 401–408
20. Zhang, H., Xie, X., Zhu, X., Zhu, J., Hao, C., Lu, Q., Ding, L., Liu, Y., Zhou, L., Liu, Y., Huang, C., Wen, C., and Ye, Q. (2005) Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells. J. Biol. Chem. 280, 43188–43197
21. Burns, K. A., Li, Y., Arao, Y., Petrovich, R. M., and Korach, K. S. (2011) Selective mutations in estrogen receptor α D-domain alters nuclear translocation and non-estrogen response element gene regulatory mechanisms. J. Biol. Chem. 286, 12640–12649
22. Ding, L., Wang, Z., Yan, J., Yang, X., Liu, A., Qiu, W., Zhu, J., Han, J., Zhang, H., Lin, J., Cheng, L., Qin, X., Niu, C., Yuan, B., Wang, X., Zhu, C., Zhou, Y., Li, J., Song, H., Huang, C., and Ye, Q. (2009) Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-β-like signaling pathway. J. Clin. Invest. 119, 349–361
23. Sun, Y., Ding, L., Zhang, H., Han, J., Yang, X., Yan, J., Zhu, Y., Li, J., Song, H., Huang, C., and Ye, Q. (2006) Potentiation of Smad-mediated transcriptional activation by the RNA-binding protein RBPMs. Nucleic Acids Res. 34, 6314–6326
24. Ding, L., Yan, J., Zhu, J., Zhong, H., Lu, Q., Wang, Z., Huang, C., and Ye, Q. (2003) Ligand-independent activation of estrogen receptor α by XBP-1. Nucleic Acids Res. 31, 5266–5274
25. Cheng, L., Li, J., Han, Y., Lin, J., Niu, C., Zhou, Z., Yuan, B., Huang, K., Li, J., Jiang, K., Zhang, H., Ding, L., Xu, X., and Ye, Q. (2012) PES1 promotes breast cancer by differentially regulating ERα and ERβ. J. Clin. Invest. 122, 2857–2870
26. Levin, E. R. (2005) Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol. 19, 1951–1959
27. Stossi, F., Barnett, D. H., Frasor, J., Komm, B., Lyttle, C. R., and Katzenel-
lenbogen, B. S. (2004) Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) α or ERβ in human osteosarcoma cells: distinct and common target genes for these receptors. *Endocrinology* **145**, 3473–3486

28. Creighton, C. J., Cordero, K. E., Larios, J. M., Miller, R. S., Johnson, M. D., Chinnaiyan, A. M., Lippman, M. E., and Rae, J. M. (2006) Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenographs and human breast tumors. *Genome Biol.* **7**, R28

29. Frasor, J., Danes, J. M., Komm, B., Chang, K. C., Lyttle, C. R., and Katzenellenbogen, B. S. (2003) Profiling of estrogen up- and down-regulated genes in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. *Endocrinology* **144**, 4562–4574

30. Carroll, J. S., and Brown, M. (2006) Estrogen receptor target gene: an evolving concept. *Mol. Endocrinol.* **20**, 1707–1714

31. Song, R. X., Zhang, Z., Chen, Y., Bao, Y., and Santen, R. J. (2007) Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF7 breast cancer cells. *Endocrinology* **148**, 4091–4101

32. Boulware, M. I., Kordasiewicz, H., and Mermelstein, P. G. (2007) Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neurons. *J. Neurosci.* **27**, 9941–9950

33. Schlegel, A., Wang, C., Katzenellenbogen, B. S., Pestell, R. G., and Lisanti, M. P. (1999) Caveolin-1 potentiates estrogen receptor α (ERα) signaling. Caveolin-1 drives ligand-independent nuclear translocation and activation of ERα. *J. Biol. Chem.* **274**, 33551–33556

34. Lu, Q., Pallas, D. C., Surks, H. K., Baur, W. E., Mendelsohn, M. E., and Karas, R. H. (2004) Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor α. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 17126–17131

35. Cabodi, S., Moro, L., Baj, G., Smeriglio, M., Di Stefano, P., Gippone, S., Surico, N., Silengo, L., Turco, E., Tarone, G., and DeFilippi, P. (2004) p130Cas interacts with estrogen receptor α and modulates non-genomic estrogen signaling in breast cancer cells. *J. Cell Sci.* **117**, 1603–1611

36. Song, R. X., Barnes, C. J., Zhang, Z., Bao, Y., Kumar, R., and Santen, R. J. (2004) The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 2076–2081

37. Manavathi, B., Acconcia, F., Rayala, S. K., and Kumar, R. (2006) An inherent role of microtubule network in the action of nuclear receptor. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 15981–15986

38. Wang, X., Yang, Z., Zhang, H., Ding, L., Li, X., Zhu, C., Zheng, Y., and Ye, Q. (2008) The estrogen receptor-interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT. *Biochim. Biophys. Acta* **1783**, 1220–1228

39. Fox, E. M., Andrade, J., and Shupnik, M. A. (2009) Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. *Steroids* **74**, 622–627

40. Osborne, C. K., Shou, J., Massarweh, S., and Schiff, R. (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. *Clin. Cancer Res.* **11**, 8658–8708

41. Murphy, L. C., Seekallu, S. V., and Watson, P. H. (2011) Clinical significance of estrogen receptor phosphorylation. *Endocr. Relat. Cancer.* **18**, R1–R14

42. de Leeuw, R., Neeffes, J., and Michalides, R. (2011) A role for estrogen receptor phosphorylation in the resistance to tamoxifen. *Int. J. Breast Cancer* **2012**, 1–10

43. De, Luca, M. R., D’Alessio, A., Pergameno, M., and Nornmano, N. (2012) The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. *Expert Opin. Ther. Targets* **16**, S17–S27

44. Milde-Langosch, K. (2005) The Fox family of transcription factors and their role in tumourigenesis. *Eur. J. Cancer* **41**, 2449–2461

45. Lopez-Berardi, P., Lau, E., and Ronai, Z. (2010) Emerging roles of ATF2 and the dynamic AP1 network in cancer. *Nat. Rev. Cancer* **10**, 65–76

46. Musgrove, E. A., Corden, C. E., Barraclough, J., Stone, A., and Sutherland, R. L. (2011) Cyclin D as a therapeutic target in cancer. *Nat. Rev. Cancer* **11**, 558–572

47. Meyer, N., and Penn, L. Z. (2008) Reflecting on 25 years with MYC. *Nat. Rev. Cancer* **8**, 976–990

48. Mandal, S., and Davie, J. R. (2007) An integrated analysis of genes and pathways exhibiting metabolic differences between estrogen receptor positive breast cancer cells. *BMC Cancer* **7**, 1471–1477

49. Huang, X., Gao, L., Wang, S., McManaman, J. L., Thor, A. D., Yang, X., Esteves, F. J., and Liu, B. (2010) Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-1 receptor in breast cancer cells resistant to herceptin. *Cancer Res.* **70**, 1204–1214

50. Vogel, C., Chan, A., Gril, B., Kim, S. B., Kurebayashi, J., Liu, L., Lu, Y. S., and Moon, H. (2010) Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. *Jpn. J. Clin. Oncol.* **40**, 999–1013